Monoclonal antibodies, biologics like dupilumab, adalimumab, and omalizumab, have transformed medicine across dozens of conditions in the past three decades. Understanding what they are helps patients make sense of why these drugs work differently from traditional medications.
What Is an Antibody?
Antibodies are proteins produced by the immune system to identify and neutralize specific threats, bacteria, viruses, or other targets. Each antibody recognizes a precise molecular target (antigen) with extraordinary specificity, like a lock and a key.
What Makes a Monoclonal Antibody?
“Monoclonal” means “from a single clone”, a large population of identical antibodies that all recognize the same specific target. In contrast, the natural antibody response (polyclonal) produces a mixture targeting different parts of the same antigen.
Monoclonal antibodies are manufactured using hybridoma technology or recombinant DNA techniques, producing highly pure, highly specific therapeutic agents in industrial quantities.
Why Monoclonal Antibodies Are Powerful
The specificity of monoclonal antibodies allows them to: – Target a single protein or receptor with extraordinary precision – Block a specific inflammatory signaling molecule without broadly suppressing the immune system – Produce efficacy with a more favorable side effect profile than broad immunosuppressants
Examples in Skin and Kidney Conditions
Dupilumab (Dupixent), targets the IL-4 receptor alpha subunit, blocking IL-4 and IL-13 signaling. Approved for atopic dermatitis, asthma, and prurigo nodularis.
Omalizumab (Xolair), targets IgE, reducing allergic sensitization. Approved for chronic spontaneous urticaria.
Secukinumab (Cosentyx), targets IL-17A. Approved for psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
See current studies and apply to explore whether a biologic clinical trial may be right for you.